With supply chains disrupted and the world veering all its attention towards halting Covid-19, FDI flows into the pharmaceutical sector will strongly depend on countries’ ability to respond to the epidemic, and their overall stability. “Biopharma FDI is a major driver for economic growth for many countries planning to build up or strengthen their biopharmaceutical sectors,” says head of international headquarters for KPMG Switzerland André Guedel, who specialises in life sciences activity. “Especially in the manufacturing area for APIs and for finished products, there will now be opportunities for countries that can provide a qualified workforce, and for political and financial stability. “Biopharmaceutical companies will review their